Galanin: profile of a new neuropeptide

Direct stimulation of growth hormone secretion by galanin in the domestic fowl*

Abstract Galanin, a novel peptide originally isolated from porcine intestine, has a wide distribution in the nervous system and is known to enhance the release of growth hormone in mammals, though the mechanism of its actions is still subject to debate. In the current study, the effects of galanin on growth hormone secretion in the domestic fowl were investigated. Intravenous injections of galanin into both 8-week old and 18-week old female Hubbard broilers produced marked increases in plasma growth hormone, similar in magnitude to that evoked by human growth hormone-releasing factor. Galanin produced dose-related increases in growth hormone release, with a peak response occurring within 10 min of administration. Growth hormone release in response to a maximal challenge of growth hormone-releasing factor was further augmented when galanin was given at the same time. Galanin stimulated growth hormone release from chick hemipituitary glands in vitro, a response which was not dependent upon hypothalamic input. In addition, galanin potentiated the actions of growth hormone-releasing factor on growth hormone release in vitro and these responses were reversed by somatostatin. These results show that galanin is able to stimulate growth hormone release in the domestic fowl by acting directly on the pituitary gland.

Analysis of the ontogeny of galanin in the rat central nervous system by immunohistochemistry and radioimmunoassay

The development of galanin-like immunoreactivity in the rat central nervous system has been investigated immunologically. Galanin-positive processes in the central nervous system were first recognized at day 1 post-natal, in the dorsal horn of the spinal cord. At day 2, the first galanin-immunoreactive neuronal somata were visualized in several regions of the diencephalon; at later stages of maturation positive cells were also detected in many brain stem areas. The number, density and staining intensity of galanin-positive structures in these and other regions increased steadily until day 28, by which age the adult disposition was attained. Increases in the concentrations of galanin-like immunoreactivity during maturation of the animals closely paralleled the immunohistochemical findings. No reduction in galanin-like immunoreactivity was noted in any area during later post-natal ages. The present study indicates that the ontogeny of galanin-like immunoreactivity in the rat central nervous system occurs entirely post-natally. The developmental profile is consistent with the role of galanin as a putative neurotransmitter/neuromodulator in the rat brain and spinal cord.

Structural requirements for galanin interaction with receptors from pancreatic beta cells and from brain tissue of the rat

The binding activity of several galanin fragments and analogs was measured on specific receptors present in rat brain and the rat pancreatic beta cell line Rin m 5F. In both tissues it was observed that: 1) galanin(3-29), galanin(10-29) and [Ile2]-galanin were ineffective for inhibiting [125I] galanin binding and 2) active peptides had the following rank order of potency: galanin(1-29) greater than [Ac-Trp2]-galanin(2-29) greater than galanin(2-29) greater than galanin(1-15) greater than [Phe2]-galanin greater than [Tyr2]-galanin. It was concluded that the N-terminal portion of galanin is very important for interaction with central or peripheral receptors. The aromatic amino acid in position 2 (Trp in native galanin) plays a crucial role.

Mechanism of galanin-inhibited insulin release. Occurrence of a pertussis-toxin-sensitive inhibition of adenylate cyclase

In the insulin-secreting beta cell line Rin m 5F, galanin, a newly discovered ubiquitous neuropeptide, inhibited, by 50%, the stimulation of insulin release induced by gastric inhibitory polypeptide (GIP) or forskolin, i.e. two cAMP-generating effectors. In contrast, it failed to decrease the stimulation of insulin release elicited by either the Ca2+-mobilizing agent, carbamoylcholine, or by dibutyryl-cAMP. Concomitantly, galanin inhibited the GIP- and forskolin-stimulated cAMP production. Furthermore, adenylate cyclase in membranes from Rin m 5F cells was highly sensitive to galanin, which exerted a marked inhibitory effect on the forskolin-stimulated enzyme activity. All these galanin effects were observed at low physiological doses, in the nanomolar range. Overnight treatment of the Rin m 5F cells with pertussis toxin completely abolished the inhibitory effect of galanin on insulin release, cAMP production and adenylate cyclase activity. Moreover, pertussis toxin specifically ADP-ribosylated a 39-kDa protein present in membranes from those cells. Taken together, these data show that the galanin inhibition of insulin release most likely occurs through the inhibition of adenylate cyclase, involving a petussis-toxin-sensitive inhibitory GTP-binding regulatory protein.